França Neto, Olímpio R. http://orcid.org/0009-0005-4855-8585
Fernandes-Silva, Miguel M. http://orcid.org/0000-0002-0095-9049
Cerci, Rodrigo J. http://orcid.org/0000-0002-3913-7181
Cunha-Pereira, Carlos A. http://orcid.org/0009-0005-3654-5883
Masukawa, Margaret http://orcid.org/0000-0002-4934-9305
Vitola, João V. http://orcid.org/0000-0003-4079-8478
Article History
Received: 28 November 2023
Accepted: 22 February 2024
First Online: 22 March 2024
Declarations
:
: Olímpio R. França Neto has received consulting fees and a speaker honorarium from Les Laboratoires Servier. Miguel M. Fernandes-Silva has received consulting or personal lecture fees from AstraZeneca, Bayer, Boehringer, and Novartis. Rodrigo J. Cerci, Carlos A. Cunha-Pereira, Margaret Masukawa, and João V. Vítola declare no conflicts of interest.
: After providing written informed consent, patients entered the study. Patients received background therapy for CCS according to contemporary guidelines. The study was approved by the Research Ethics Committee of the Hospital de Clinicas da Universidade Federal do Paraná, in Curitiba, Paraná, Brazil (ethics approval number 3.182.920) and all procedures followed were in accordance with the Helsinki Declaration of 1964, as revised in 2013.